Safety and exploratory efficacy of EHT 0202 in mild to moderate Alzheimers patients: a 3-month.

Vellas B, Ousset PJ, Desire L, Pando M. Safety and exploratory efficacy of EHT 0202 in mild to moderate Alzheimer’s patients: a 3-month, randomized, double – blind, placebo-controlled, phase IIa trial. Presented at the Second Conference of Clinical Trials on Alzheimer ‘s Disease in Las Vegas, October 2009.

This first patient data support the advancement of EHT 0202 in the Phase IIb and ExonHit is in talks with potential partners for the further development and commercialization of EHT 0202nd.Made very good progress EMA the Orphan Drug Designation of FP110.

This granted Orphan Drug Designation follows a similar pattern decision by the Food and Drug Administration . It is another important milestone the program, received under promising results a Phase 2a clinical trial with patients with pouchitis. Pouchitis is a debilitating disease for the is no approved treat and reflected of IAS decisions also high unmet medical need of patients with the disease.

Image areas research could from multi – functional sensing instrument Benefitresearch with its innovative, multi-functional sensing search engine adenosine triphosphate release and the role to examine in cystic fibrosis. The ATP trial is the first application of a new measurement system by a team out of Christine Kranz the Georgia Institute of Technology developed.

Published by